Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Get Free Report)'s stock price was up 7.4% during mid-day trading on Wednesday . The stock traded as high as $4.50 and last traded at $3.78. Approximately 34,951 shares changed hands during mid-day trading, an increase of 500% from the average daily volume of 5,830 shares. The stock had previously closed at $3.52.
Genenta Science Price Performance
The company has a 50-day moving average price of $3.67 and a 200-day moving average price of $3.86.
Institutional Investors Weigh In On Genenta Science
Hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of Genenta Science in the fourth quarter valued at about $46,000. Algebris UK Ltd grew its position in shares of Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Allianz SE grew its position in Genenta Science by 126.2% during the first quarter. Allianz SE now owns 233,550 shares of the company's stock worth $927,000 after buying an additional 130,300 shares in the last quarter. 15.13% of the stock is owned by institutional investors and hedge funds.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
